Inactive Instrument

NICOX Stock Swiss Exchange

OXCOX

FR0000074130

News in other languages: NICOX

Sep. 16	Nicox va présenter des données sur le NCX 470 lors d'un congrès
Sep. 16	Nicox : Les données sur NCX 470 seront présentées lors du Congrès annuel 2026 de l’AAOpt
Sep. 11	Bourse : Alstom et Airbus engrangent de gros contrats, Oracle rassure
Sep. 11	Nicox obtient une autorisation en Chine
Sep. 11	Very bad trip en bourse ?

More news

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX	-.--%	-.--%	-	-	34.59M
MERCK & CO., INC.	-1.88%	+2.19%	+85.19%	+39.25%	372B
MERCK KGAA	-0.15%	+0.95%	+19.61%	-16.49%	66.24B
HALOZYME THERAPEUTICS, INC.	-2.34%	+3.69%	+44.95%	+184.15%	13.07B
KYOWA KIRIN CO., LTD.	+0.71%	+0.44%	-1.41%	-15.83%	7.51B
SK BIOPHARMACEUTICALS CO., LTD.	-1.30%	-2.94%	-31.19%	-12.05%	4.44B
YUHAN CORPORATION	-1.33%	-4.14%	-39.81%	+5.86%	4.13B
BETTA PHARMACEUTICALS CO., LTD.	-0.71%	+6.63%	-24.79%	-7.60%	3.18B
SUPERNUS PHARMACEUTICALS, INC.	-0.82%	+4.86%	-7.35%	+54.03%	2.54B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.29%	+0.36%	-19.65%	-32.22%	1.98B
Average	-0.91%	+1.71%	+2.84%	+22.12%	52.82B
Weighted average by Cap.	-1.58%	+2.00%	+69.74%	+33.30%

See all sector performances

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Market Cap	29.61M 33.74M 27.84M 25.45M 47.56M 3.23B 47.91M 334M 130M 1.65B 127M 124M 5.34B	P/E 2026 *	-6.72x	P/E 2027 *	16.8x
Enterprise Value	29.61M 33.74M 27.84M 25.45M 47.56M 3.23B 47.91M 334M 130M 1.65B 127M 124M 5.34B	EV / Sales 2026 *	9.87x	EV / Sales 2027 *	2.96x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

Sep. 16	Nicox to present NCX 470 data at a conference
Sep. 11	Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review	MT
Sep. 11	Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China	CI
Sep. 11	Nicox wins regulatory acceptance in China
Sep. 02	Nicox S.A. Announces Appointment of Doug Hubatsch as Chief Scientific Advisor	CI
Aug. 27	The FDA will issue its decision on Nicox's NCX 470 by the end of next April
Aug. 27	US FDA to Complete Nicox's Glaucoma Drug Review by April 2027	MT
Aug. 27	Nicox S.A. Announces U.S. Food and Drug Administration Accepts the New Drug Application for NCX 470	CI
Aug. 10	Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China	CI
Aug. 10	Nicox Partner Files China Drug Application for NCX 470 Eye Drop	MT
Aug. 10	A Nicox partner has cleared an important milestone in China
Jul. 01	Nicox Submits NCX 470 New Drug Application In The United States	CI
Jul. 01	Nicox files U.S. marketing approval application

Sep. 16	Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026	GL
Sep. 11	Nicox Announces NCX 470 NDA in China Accepted for Review	GL
Sep. 02	Nicox Announces Extension of Cash Runway	GL
Aug. 27	Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma	GL
Aug. 10	Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension	GL

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	2024-02-27
Sandrine Gestin DFI	Director of Finance/CFO	58	2014-12-31
Emmet Purtill PRN	Corporate Officer/Principal	-	2005-12-31

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	2024-04-07
Damian Marron CHM	Chairman	64	2024-07-15
Marc Bozec BRD	Director/Board Member	-	2024-07-15

NICOX Stock Swiss Exchange

Stocks

OXCOX

FR0000074130

Pharmaceuticals

Valuation: NICOX

Latest news: NICOX

Press Releases: NICOX

News in other languages: NICOX

Managers and Directors: NICOX

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

	2026 *	2027 *
Net sales	3M 3.42M 2.82M 2.58M 4.82M 327M 4.85M 33.87M 13.13M 167M 12.84M 12.55M 541M	10M 11.39M 9.4M 8.59M 16.06M 1.09B 16.18M 113M 43.77M 556M 42.79M 41.85M 1.8B
Net income	-5M -5.7M -4.7M -4.3M -8.03M -546M -8.09M -56.45M -21.89M -278M -21.39M -20.92M -902M	2M 2.28M 1.88M 1.72M 3.21M 218M 3.24M 22.58M 8.75M 111M 8.56M 8.37M 361M
Net Debt	-	-